Immucor Inc. (BLUD) announced Friday morning that the FDA issued a notice of intent to revoke the company's biologics license with respect to its Reagent Red Blood Cells and Anti-E Blood Grouping Reagent product.
Immucor Inc. gapped open sharply lower Friday, but was range-bound for the majority of the session. Shares finished down by $2.29 at $13.80 on strong volume. Immucor dropped below a 2-month range and closed at a new low for the year.
For comments and feedback: editorial@rttnews.com